FKBPL and ovarian carcinoma: Studies on ovarian cancer have shown that FKBPL therapeutic peptide derivatives stimulate the differentiation of ovarian CSCs and decrease their numbers while delaying tumor initiation and the growth of highly vascularized xenografts, in conclusion, establishing their antitumor effect through the disruption of angiogenesis [15].